Uncovering the Potential of a KRAS G12C Inhibitor in Combination of SHP2 Inhibitor for Treatment of NSCLC
- Understanding the rationale of KRAS G12C plus SHP2 in NSCLC
- Examining the preclinical data of this combination
- Presenting the phase I/IIa results of the combination in NSCLC